Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Watch Out, Eli Lilly and Novo Nordisk: Amgens Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and Its Coming for Your Patients

Will this pharma company become a new leader in the weight loss market?…

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnsons revenue has grown modestly while Eli Lillys revenue has nearly doubled in two years, narrowing a once-wide…

Goldman Sachs sees writing on the wall for Eli Lilly stock

Eli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on…

Eli Lilly, Dell Lead Five Stocks To Watch As Leadership Shifts

As AI-related stocks weaken, new leaders emerge.…

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity ?and diabetes drug…

Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people…

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of…

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Heres What That Means for Both Stocks.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.…

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Eli Lillys GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.…

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective…

Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising

The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.…

Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1…

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

LLYs leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO…

Heres Why Eli Lilly (LLY) Fell More Than Broader Market

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.…

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.…

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

Theres a good reason why investors are focused on Eli Lillys GLP-1 business, but theres more going on at the…

Wegovy Pill Just Changed the GLP-1 Market. Heres Why Eli Lilly Stock Could Still Win

Novo Nordisk is finally getting one up on its biggest rival.…

Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.…

Eli Lillys $3.8bn psychedelics bet is built on British science

Eli Lillys first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a…

AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies...…

AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies...…

Eli Lilly: Frontalangriff auf Johnson & Johnson im Markt für Depressionstherapien

Eli Lilly diversifiziert sein Geschäftsmodell über die Abnehm- und Diabetesmedikamente hinaus mit einer aggressiven Übernahmestrategie. Die Übernahme von AtaiBeckley…

UBS strongly resets Lilly stock target

Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July.  Guggenheim, Truist, Bank of America,…

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly said on Thursday it would buy AtaiBeckley for ?up to $3.8 billion, entering the race to develop psychedelic…

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedelic…

AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at…

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its…

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eyes are on the rollout of Lillys new weight loss pill.…

Heres How Much Eli Lillys Weight-Loss Drugs Are Worth to Investors

Two drugs now generate almost two-thirds of the pharmaceutical giants revenue.…

Should You Buy Eli Lilly Stock? Heres My Honest Take.

There are good reasons to invest in Lilly and to hold off.…

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.…

JPMorgan resets LLY stock target on drug demand

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well.  On Tuesday, one…

Is It Too Late to Buy Eli Lilly?

The stock has soared 400% in recent years.…

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Eli Lillys next leg of growth may have less to do with how well its weight loss drugs work and…

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.…

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the…

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.…

Top Stock Reports for Eli Lilly, HSBC & Palantir

Eli Lilly, HSBC and Palantir headline Zacks latest top stock reports, highlighting growth drivers, opportunities and key risks shaping each…

Lilly quietly hands Chinese partner its cancer drug

Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its…

House committee investigates Merck, AbbVie over China trials

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China…

OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCRs David Bautz

NASDAQ: MTVAGreg Young: Hello and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…

Can Eli Lillys New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term…

Ranking Wall Streets Trillion-Dollar Stocks From Most to Least Attractive, Based on Future Cash Flow

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are…

Medicare will start covering obesity drugs for the first time. Heres what patients should know

The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that…

5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX

SpaceX recently completed a record IPO.…

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC…

Medicare deckt ab Juli GLP-1 Präparate von Eli Lilly ab! Morgan Stanley erhöht Marktvolumen auf 190 Mrd. USD!

Meilenstein in den USA: Ab Juli 2026 erhalten Mio. Senioren über das Medicare-Bridge-Programm Zugang zu GLP-1-Präparaten für nur 50…

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the…

Why Eli Lilly Gained 7% On Friday

…